Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBX 2109 in renal impairment
NCT06496217Phase 1Completed
- Sponsor
- MBX Biosciences, Inc.
- Start
- Jun 2024
- Primary completion
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of canvuparatide (4 arms), sponsored by MBX Biosciences, Inc. Primary endpoints: Area under the plasma concentration-time curve from time 0 extrapolated to infinity at 36 days, Maximum observed concentration at 36 days and 5 more. Started Jun 2024; status: completed.
02
Drugs
canvuparatide
Beyond the preview
Go deeper on NCT06496217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496217.